### Clinical Extent of disease before any treatment

<table>
<thead>
<tr>
<th>Stage Category Definitions</th>
<th>Pathologic Extent of disease through completion of definitive surgery</th>
</tr>
</thead>
</table>

- **Tumor Size:** __________

#### PRIMARY TUMOR (T)

- **TX** Primary tumor cannot be assessed
- **T0** No evidence of primary tumor
- **Tis** Carcinoma in situ*
- **T1** Tumor limited to the pancreas, 2 cm or less in greatest dimension
- **T2** Tumor limited to the pancreas, more than 2 cm in greatest dimension
- **T3** Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery
- **T4** Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor)

*Note: This also includes the “PanInIII” classification

#### REGIONAL LYMPH NODES (N)

- **NX** Regional lymph nodes cannot be assessed
- **N0** No regional lymph node metastasis
- **N1** Regional lymph node metastasis

#### DISTANT METASTASIS (M)

- **M0** No distant metastasis (no pathologic M0; use clinical M to complete stage group)
- **M1** Distant metastasis

### Anatomic Stage • Prognostic Groups

#### Clinical

- **GROUP 0** Tis N0 M0
- **GROUP IA** T1 N0 M0
- **GROUP IB** T2 N0 M0
- **GROUP IIA** T3 N0 M0
- **GROUP IIB** T1 N1 M0
- **GROUP III** T4 Any N M0
- **GROUP IV** Any T Any N M1
- **Stage unknown**

#### Pathologic

- **GROUP 0** Tis N0 M0
- **GROUP IA** T1 N0 M0
- **GROUP IB** T2 N0 M0
- **GROUP IIA** T3 N0 M0
- **GROUP IIB** T1 N1 M0
- **GROUP III** T4 Any N M0
- **GROUP IV** Any T Any N M1
- **Stage unknown**

### Hospital Name/Address

<table>
<thead>
<tr>
<th>Hospital Name/Address</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Patient Name/Information</th>
</tr>
</thead>
</table>

(continued on next page)
## Pancreas Staging Form

### Prognostic Factors (Site-Specific Factors)

**Required for Staging:** None

**Clinically Significant:**
- Preoperative CA 19-9
- Preoperative Carcinoembryonic Antigen (CEA)
- Preoperative plasma chromogranin A level (CgA) (endocrine pancreas)
- Mitotic count (endocrine pancreas)

### Additional Descriptors

**Histologic Grade (G)** (also known as overall grade)

- 2 grade system
- 3 grade system
- 4 grade system
- No 2, 3, or 4 grade system is available

**Grading System**
- Grade I or 1
- Grade II or 2
- Grade III or 3
- Grade IV or 4

### General Notes:

For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

- **m suffix** indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
- **y prefix** indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.
- **r prefix** indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.
- **a prefix** designates the stage determined at autopsy: aTNM.

### Additional Descriptors

**Lymphatic Vessel Invasion (L) and Venous Invasion (V)** have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- Lymph-Vascular Invasion Not Present (absent)/Not Identified
- Lymph-Vascular Invasion Present/Identified
- Not Applicable
- Unknown/Indeterminate

**Residual Tumor (R)**

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

- Clinical stage was used in treatment planning (describe):

- National guidelines were used in treatment planning
  - NCCN
  - Other (describe):

---

Physician signature

Date/Time

---

**Hospital Name/Address**

**Patient Name/Information**
Illustration
Indicate on diagram primary tumor and regional nodes involved.